- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Moderna Inc's MRNA COVID-19 vaccine (Spikevax) for use in adolescents 12 years of age and older.
- Following the CHMP's positive opinion, the European Commission will consider the vaccine's approval in adolescents.
- Moderna is also conducting a Phase 2/3 study, called the KidCOVE study, of mRNA-1273 in children ages six months to less than 12 years.
- Price Action: MRNA shares are up 2.89% at 332.83 during the market session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
- Photo by Wilfried Pohnke from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
